Floatz logo

INTERFERON-ALFA-2A

Renal Cell Cancer

Central European Society for Anticancer Drug Researchprotein_peptidePhase 3Dormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

298 Active assets in the Renal Cell Cancer cohort.

Asset / SponsorPhaseRating
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

INTERFERON-ALFA-2A is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →
kidney cancerDormant
B
Indicative ·
62 / 100
View asset →
lymphomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →